Proliferating focus of the scientists towards precision medicine is offering growth opportunities for the global brain tumour therapeutics industry. Additionally, factors such as greater per capita healthcare spending, improved healthcare infrastructure and rising awareness of advanced technologies will further upsurge the market growth.
The global brain tumor therapeutics market is expected to be around US$ 755 million in 2028 at CAGR 8%.
Globally, rising number of patients with brain cancer is escalating the brain tumour therapeutics market size. For instance, according to San Diego Brain Tumour Foundation estimation, in 2018, more than 688,000 people in the U.S. are living with central nervous system or primary brain tumours diagnosis.
Global brain tumour therapeutics market is segmented based on the product as, Cell based and Acellular. On the basis of therapy, the global brain tumour therapeutics market is segregated as cell therapy, tissue engineering, immunotherapy, and gene therapy. Central nervous system diseases are expected to witness notable gains in the forecast years. The report segments global brain tumour therapeutics market based on application as orthopedic & musculoskeletal disorders, dermatology, cardiology, central nervous system diseases, oncology, diabetes.
Global brain tumour therapeutics market report covers various regions including North America, Europe, Asia Pacific, and Rest of World. The regional brain tumour therapeutics market is further bifurcated for major countries including U.S., Canada, Germany, UK, France, Italy, China, India, Japan, Brazil, South Africa and others.
Competitive Rivalry
Global brain tumour therapeutics market share consists of several players including Pfizer, Novartis, F. Hoffman La-Roche, Merck & Co., Immunocellular Therapeutics., Novocure, Del Mar Pharmaceuticals, and Moleculin Biotech.
The Brain Tumour Therapeutics Market has been segmented as below:
Brain Tumour Therapeutics Market, By Product
Brain Tumour Therapeutics Market, By Therapy
Brain Tumour Therapeutics Market, By Application
Brain Tumour Therapeutics Market, By Region
The report covers:
Report scope:
The global brain tumour therapeutics market report covers detailed study with the underlying influencing factors for the variations in the industry growth trends.
The report scope includes market analysis on regional as well as country level. The report also provides competitive landscape covering company market shares with detailed profiling for major revenue contributing companies.
The report covers a detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Pfizer, Novartis, F. Hoffman La-Roche, Merck & Co., Immunocellular Therapeutics., Novocure, Del Mar Pharmaceuticals, and Moleculin Biotech.
Reasons to Buy this Report:
Customization:
Customized report as per the requirement can be offered with appropriate recommendations
Below are our New Reports :-
1. Introduction
1.1. Key Points
1.2. Report Description
1.3. Markets Covered
1.4. Stakeholders
2. Research Methodology
2.1. Research Scope
2.2. Research Methodology
2.2.1. Market Research Process
2.2.2. Research Methodology
2.2.2.1. Secondary Research
2.2.2.2. Primary Research
2.2.2.3. Models for Estimation
2.3. Market Size Estimation
2.3.1. Bottom-Up Approach
2.3.2. Top-Down Approach
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Drivers
4.2.1. Increasing adoption of stem cell technology
4.2.2. Rising prevalence of chronic diseases
4.2.3. Emerging applications of gene therapy in regenerative medicine
4.3. Restraints
4.3.1. Regulatory and ethical issues
4.4. Opportunities
4.4.1. Technological advancements
4.5. Challenges
4.5.1. Prohibited costs
5. Brain Tumor Therapeutics Market, By Product
5.1. Key Points
5.2. Cell based
5.3. Acellular
6. Brain Tumor Therapeutics Market, By Therapy
6.1. Key Points
6.2. Cell Therapy
6.3. Tissue Engineering
6.4. Immunotherapy
6.5. Gene Therapy
7. Brain Tumor Therapeutics Market, By Application
7.1. Key Points
7.2. Orthopedic & Musculoskeletal Disorders
7.3. Dermatology
7.4. Cardiology
7.5. Central Nervous System Diseases
7.6. Oncology
7.7. Diabetes
8. Competitive Landscape
8.1. Introduction
8.2. Recent Developments
8.2.1. Mergers & Acquisitions
8.2.2. New Product Developments
8.2.3. Portfolio/Production Capacity Expansions
8.2.4. Joint Ventures, Collaborations, Partnerships & Agreements
8.2.5. Others
9. Company Profile
9.1. Novartis
9.1.1. Company Overview
9.1.2. Product/Service Landscape
9.1.3. Financial Overview
9.1.4. Recent Developments
9.2. F. Hoffman La-Roche
9.2.1. Company Overview
9.2.2. Product/Service Landscape
9.2.3. Financial Overview
9.2.4. Recent Developments
9.3. Merck & Co
9.3.1. Company Overview
9.3.2. Product/Service Landscape
9.3.3. Financial Overview
9.3.4. Recent Developments
9.4. Immunocellular Therapeutics
9.4.1. Company Overview
9.4.2. Product/Service Landscape
9.4.3. Financial Overview
9.4.4. Recent Developments
9.5. Novocure
9.5.1. Company Overview
9.5.2. Product/Service Landscape
9.5.3. Financial Overview
9.5.4. Recent Developments
9.6. Del Mar Pharmaceuticals
9.6.1. Company Overview
9.6.2. Product/Service Landscape
9.6.3. Financial Overview
9.6.4. Recent Developments
9.7. Moleculin Biotech
9.7.1. Company Overview
9.7.2. Product/Service Landscape
9.7.3. Financial Overview
9.7.4. Recent Developments
9.8. Roche
9.8.1. Company Overview
9.8.2. Product/Service Landscape
9.8.3. Financial Overview
9.8.4. Recent Developments
9.9. Pfizer
9.9.1. Company Overview
9.9.2. Product/Service Landscape
9.9.3. Financial Overview
9.9.4. Recent Developments
9.10. AstraZeneca
9.10.1. Company Overview
9.10.2. Product/Service Landscape
9.10.3. Financial Overview
9.10.4. Recent Developments
The Brain Tumour Therapeutics Market has been segmented as below:
Brain Tumour Therapeutics Market, By Product
Brain Tumour Therapeutics Market, By Therapy
Brain Tumour Therapeutics Market, By Application
Brain Tumour Therapeutics Market, By Region
SUBSCRIBE TO OUR NEWSLETTERS
